Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
5.99
-0.09 (-1.56%)
At close: May 9, 2025, 4:00 PM
6.09
+0.10 (1.75%)
After-hours: May 9, 2025, 7:02 PM EDT
Amicus Therapeutics Stock Forecast
Stock Price Forecast
According to 9 professional analysts, the 12-month price target for Amicus Therapeutics stock ranges from a low of $9.00 to a high of $22. The average price target of $16.22 forecasts a 171.01% increase in the stock price over the next year.
Price Target: $16.22 (+171.01%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Amicus Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 2 | 2 | 2 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 9 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $21 → $22 | Strong Buy | Maintains | $21 → $22 | +267.59% | May 2, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $12 → $9 | Hold | Maintains | $12 → $9 | +50.38% | May 2, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $18 → $17 | Buy | Maintains | $18 → $17 | +184.04% | Feb 20, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Feb 20, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $21 | Buy | Reiterates | $21 | +250.88% | Jan 15, 2025 |
Financial Forecast
Revenue This Year
643.85M
from 528.30M
Increased by 21.87%
Revenue Next Year
786.69M
from 643.85M
Increased by 22.19%
EPS This Year
0.03
from -0.18
EPS Next Year
0.33
from 0.03
Increased by 900.06%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 679.4M | 848.7M | 1.1B | ||
| Avg | 643.9M | 786.7M | 959.3M | ||
| Low | 600.2M | 729.2M | 827.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 28.6% | 31.8% | 36.4% | ||
| Avg | 21.9% | 22.2% | 21.9% | ||
| Low | 13.6% | 13.3% | 5.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.12 | 0.54 | 1.06 | ||
| Avg | 0.03 | 0.33 | 0.76 | ||
| Low | -0.02 | 0.09 | 0.48 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 1,529.4% | 222.7% | ||
| Avg | - | 900.1% | 130.3% | ||
| Low | - | 168.4% | 46.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.